Article Per Year (5 Year)
p-Index From 2021 - 2026
0.61
P-Index
This Author published in this journals
All Journal Indonesian Journal of Pharmacy and Natural Product Barongko : Jurnal Ilmu Kesehatan CERATA
Annisah Mahanani
Universitas Safin Pati
Education Engineering Health Professions Medicine & Pharmacology Nursing Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Perbandingan Efektivitas Profilaksis Intermiten Klobazam Versus Diazepam pada Kejang Demam Sederhana (KDS): Systematic Review: Comparison Effectiveness of the Intermittent Prophylaxis of Clobazam Versus Diazepam in Simple Febrile Seizures (SFS): Systematic Review Sulastri; Mutia Hariani Nurjanah; Melati Apriliana Ramadhani; Arif Santoso; Rahma Diyan Martha; Rissa Laila Vifta; Annisah Mahanani
Indonesian Journal of Pharmacy and Natural Product Vol. 7 No. 02 (2024): Indonesian Journal of Pharmacy and Natural Product
Publisher : Universitas Ngudi Waluyo

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35473/ijpnp.v7i02.3308

Abstract

Febrile seizures are seizures that occur when body temperature rises (rectal temperature > 38o C). Each seizure can possibly cause epilepsy and trauma to the brain. The next priority is efforts to stop acute seizure attacks which can usually be treated with anti-seizure medication. Intermittent prophylaxis with clobazam at the onset of the first febrile seizure provides better results. This systematic review aims to review articles related to the use of intermittent prophylaxis of clobazam vs diazepam for children suffering from simple febrile seizures. The literature search method uses Google Scholar, PubMed and BMJ databases based on keywords. The selected articles were articles published between 2009-2023, full text in English, were original articles comparing the effectiveness of intermittent prophylaxis use of clobazam vs diazepam in febrile seizures in children. The results obtained were 4 articles that were relevant to the objectives of this systematic review. Data is homogeneous with RR of 0.44 (95% CI: 0.32-0.60) so that the therapeutic effectiveness of administering clobazam compared with diazepam is not significantly different even though there is a chance that the effectiveness of clobazam is 0.44 times compared with administering diazepam. The efficacy of clobazam compared to diazepam, clobazam has better advantages than diazepam in preventing recurrence of febrile seizures. Apart from that, the side effects that occur with clobazam are significantly lower, for example drowsiness and sedation. ABSTRAK Kejang demam merupakan bangkitan kejang yang terjadi pada kenaikan suhu tubuh (suhu rektal > 38o C). Setiap kejang kemungkinan dapat menimbulkan epilepsi dan trauma pada otak. Prioritas selanjutnya berupa usaha untuk menghentikan serangan kejang akut yang biasanya dapat ditangani dengan pemberian obat anti kejang. Pemberian profilaksis intermiten dengan klobazam pada permulaan terjadinya kejang demam pertama memberikan hasil yang lebih baik. Systematic review  ini bertujuan untuk mereview artikel-artikel terkait adanya penggunaan profilaksis intermiten klobazam vs diazepam untuk anak penderita kejang demam sederhana. Pencarian literatur menggunakan metode berupa database Google scholar,  PubMed dan BMJ berdasarkan keywords. Artikel yang dipilih adalah artikel yang dipublikasikan antara tahun 2009-2023, fulltext dalam inggris, merupakan original article yang membandingkan efektivitas antara penggunaan profilaksis intermiten klobazam vs diazepam pada kejang demam pada anak. Hasil diperoleh 4 artikel yang relevan terhadap tujuan systematic review ini. Data bersifat homogen dengan RR 0,44 (CI 95%: 0,32-0,60) sehingga efektivitas terapi pemberian klobazam dibandingkan dengan diazepam tidak berbeda bermakna meskipun terdapat peluang efektivitas klobazam sebesar 0,44 kali dibandingkan dengan pemberian diazepam. Kemanjuran klobazam dibandingkan dengan diazepam, klobazam memiliki keunggulan lebih baik dibandingkan diazepam dalam mencegah kekambuhan kejang demam. Selain itu efek samping yang timbul pada klobazam secara signifikan jauh lebih rendah misalnya seperti mengantuk dan sedasi.
Description of Post-Immunization Adverse Events Who Received the Vaccine COVID-19 at the Tegalrejo Community Health Chotijatun Nasriyah; Astri Rachmawati; Catharina Apriyani; Raden Roro Erni Kusuma Putri; Annisah Mahanani
CERATA Jurnal Ilmu Farmasi Vol 17 No 1 (2026): Cerata Jurnal Ilmu Farmasi
Publisher : Universitas Muhammadiyah Klaten

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.61902/cerata.v17i1.1765

Abstract

Corona virus 19 (Covid-19) is an infectious disease caused by a new type of corona virus. The cause of this new virus was unknown before it became an outbreak in Wuhan in December 2019. One way to overcome the Covid 19 infection is by administering a vaccine. Post-Immunization Adverse Events are medical events that are thought to be related to Covid-19 vaccination. Post-Immunization Adverse Events that appear after vaccination are much milder than if infected with Covid-19 or complications caused by the virus. Not everyone who is vaccinated against Covid-19 experiences post-vaccination side events.The aim of this research is to look at the follow-up events after Covid-19 vaccination. This research method is descriptive by collecting data using a questionnaire which will be filled in by the respondent. The research sample was people who had received the second Covid-19 booster vaccine and were undergoing outpatient treatment at the internal medicine clinic at the Tegalrejo Community Health Center, Yogyakarta. The total sample taken was 100 respondents and divided into the type of IndoVac vaccine, 1 respondent (1%); Sinopharm 2 respondents (2%); Pfizer and Astra each with 21 respondents (21%); Moderna 23 respondents (23%) and Sinovac 32 respondents (32%). Of the six types of vaccines, all types of vaccines experienced side effects after immunization such as pain at the injection site. For the Moderna and Pfizer vaccine types, the most people experienced fever, namely 11 respondents for each type of vaccine. The conclusion is that almost all types of Covid-19 vaccines given by the community at the Tegalrejo Community Health Center in the second booster experienced post-immunization side events such as pain at the injection site and fever
Intervensi Edukasi Klinis Berbasis Pharmaceutical Care Guna Meminimalkan Risiko Medication Error Pascadispensing Terkait Beyond Use Date (BUD) Di Apotek Karanggayam Tahun 2026: Pharmaceutical Care-Based Clinical Educational Intervention to Minimize Post-Dispensing Medication Error Risks Related to Beyond-Use Date (BUD) at Karanggayam Pharmacy in 2026 Annisah Mahanani; Rr. Erni Kusuma Putri; Puput Eka Suryani; Irma Nurhidayah
Barongko: Jurnal Ilmu Kesehatan Vol 5 No 1 (2026): Barongko : Jurnal Ilmu Kesehatan (November)
Publisher : Asosiasi Guru dan Dosen Seluruh Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59585/bajik.v5i1.1628

Abstract

Latar Belakang: Kesalahan penggunaan obat tidak hanya dapat terjadi pada tahap peresepan, penyiapan, dan penyerahan obat, tetapi juga setelah obat diterima oleh pasien. Salah satu masalah yang berpotensi terjadi adalah penggunaan obat yang telah melewati Beyond Use Date (BUD), khususnya pada obat yang telah dibuka, dikemas ulang, atau diracik. Pemahaman pasien mengenai BUD menjadi bagian penting dalam pelayanan kefarmasian yang berorientasi pada keselamatan pasien. Tujuan: Penelitian ini bertujuan mengetahui pengaruh edukasi klinis berbasis pharmaceutical care terhadap pengetahuan pasien dan risiko medication error pascadispensing terkait Beyond Use Date. Metode: Penelitian menggunakan metode kuantitatif quasi-experimental dengan desain one-group pretest-posttest. Penelitian melibatkan 72 pasien yang menerima obat di Apotek Karanggayam. Responden diberikan kuesioner sebelum dan sesudah edukasi klinis mengenai BUD, penyimpanan obat, pelabelan, serta pembuangan obat yang tidak digunakan. Analisis data menggunakan uji Wilcoxon Signed-Rank dengan tingkat kemaknaan 0,05. Hasil: Sebelum intervensi, sebanyak 21 responden (29,2%) memiliki pengetahuan baik, 32 responden (44,4%) memiliki pengetahuan cukup, dan 19 responden (26,4%) memiliki pengetahuan kurang. Setelah intervensi, sebanyak 57 responden (79,2%) memiliki pengetahuan baik, 13 responden (18,1%) memiliki pengetahuan cukup, dan 2 responden (2,7%) memiliki pengetahuan kurang. Nilai median pengetahuan meningkat dari 65 menjadi 88. Hasil analisis menunjukkan terdapat perbedaan yang bermakna sebelum dan sesudah intervensi (p<0,001). Kesimpulan: Edukasi klinis berbasis pharmaceutical care berpengaruh signifikan terhadap peningkatan pengetahuan pasien mengenai BUD dan berpotensi meminimalkan risiko medication error pascadispensing. Konseling mengenai BUD perlu diintegrasikan dalam pelayanan kefarmasian rutin.
Co-Authors Arif Santoso Astri Rachmawati Catharina Apriyani Chotijatun Nasriyah Irma Nurhidayah Melati Apriliana Ramadhani Mutia Hariani Nurjanah Puput Eka Suryani Raden Roro Erni Kusuma Putri Rahma Diyan Martha Rissa Laila Vifta Rr. Erni Kusuma Putri Sulastri